Skip to content
Screener

Denali Therapeutics Inc. DNLI Accounts Receivable

Accounts Receivable at other companies

Eli Lilly logo
Eli LillyLLY
$20.08B+41.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$6.57B+17.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$200M+60.7%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$219.92M+4.5%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$13.41M-18.2%

Other financials

Income statement

See full
Revenue$3.6M—
Gross profit$3.5M—
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0×0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097

FAQ

What is Denali Therapeutics Inc.'s accounts receivable?
Denali Therapeutics Inc. (DNLI) reported accounts receivable of $3.93M in Q2 2026.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.

Ask your AI about Denali Therapeutics Inc.'s accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude